Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis

Molecular and Cellular Endocrinology

Volumn 377, Issue 1-2, 2013, Pages 84-92

  Zekri, Ali ^a,b   Ghaffari, Seyed H ^a   Yousefi, Meysam ^a   Ghanizadeh Vesali, Samad ^c   Mojarrad, Majid ^d   Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Arsenic trioxide; Autocrine human growth hormone; Breast cancer; C Myc; Mammary adenocarcinoma

Indexed keywords

ARF PROTEIN; ARSENIC TRIOXIDE; GELATINASE A; GELATINASE B; HUMAN GROWTH HORMONE; MYC PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC25A; PROTEIN P53; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

EID: 84880937824     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.07.002     Document Type: Article

References (46)

1. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. P14ARF links the tumor suppressors RB and p53. Nature 1998, 395:124-125.
2. Bougen N.M., Yang T., Chen H., Lobie P.E., Perry J.K. Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. Oncol. Rep. 2011, 26:487-493.
3. Brunet-Dunand S.E., Vouyovitch C., Araneda S., Pandey V., Vidal L.J., Print C., Mertani H.C., Lobie P.E., Perry J.K. Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 2009, 150:1341-1352.
4. Campaner S., Amati B. Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div. 2012, 7(6).
5. Dizaji M.Z., Malehmir M., Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H. Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem. Res. 2012, 37:370-380.
6. Emerald B.S., Chen Y., Zhu T., Zhu Z., Lee K.O., Gluckman P.D., Lobie P.E. AlphaCP1 mediates stabilization of hTERT mRNA by autocrine human growth hormone. J. Biol. Chem. 2007, 282:680-690.
7. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D. CDC25 phosphatases as potential human oncogenes. Science 1995, 269:1575-1577.
8. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382:511-517.
9. Gazitt Y., Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology 2005, 10:205-213.
10. Ghaffari S.H., Bashash D., Dizaji M.Z., Ghavamzadeh A., Alimoghaddam K. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumor. Biol. 2012, 33:157-172.
11. Ghaffari S.H., Momeny M., Bashash D., Mirzaei R., Ghavamzadeh A., Alimoghaddam K. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 2012, 17:198-206.
12. Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H., Rostami S., Jahani M., Hosseini R., Mossavi A., Baybordi E., Khodabadeh A., Iravani M., et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann. Oncol. 2006, 17:131-134.
13. Ghavamzadeh A., Alimoghaddam K., Rostami S., Ghaffari S.H., Jahani M., Iravani M., Mousavi S.A., Bahar B., Jalili M. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 2011, 29:2753-2757.
14. Gregory M.A., Qi Y., Hann S.R. The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle 2005, 4:249-252.
15. Guerra L., Albihn A., Tronnersjo S., Yan Q., Guidi R., Stenerlow B., Sterzenbach T., Josenhans C., Fox J.G., Schauer D.B., et al. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS One 2010, 5:e8924.
16. Harvey S. Extrapituitary growth hormone. Endocrine 2010, 38:335-359.
17. Hermeking H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 2003, 3:163-175.
18. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
19. Kaulsay K.K., Mertani H.C., Tornell J., Morel G., Lee K.O., Lobie P.E. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp. Cell. Res. 1999, 250:35-50.
20. Li Y.M., Broome J.D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999, 59:776-780.
21. Li Z., Piao F., Liu S., Wang Y., Qu S. Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice. Exp. Toxicol. Pathol. 2010, 62:543-547.
22. Menashe I., Maeder D., Garcia-Closas M., Figueroa J.D., Bhattacharjee S., Rotunno M., Kraft P., Hunter D.J., Chanock S.J., Rosenberg P.S., et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 2010, 70:4453-4459.
23. Mitchell K.O., Ricci M.S., Miyashita T., Dicker D.T., Jin Z., Reed J.C., El-Deiry W.S. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 2000, 60:6318-6325.
24. Mojarrad M., Momeny M., Mansuri F., Abdolazimi Y., Tabrizi M.H., Ghaffari S.H., Tavangar S.M., Modarressi M.H. Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med. Oncol. 2010, 27:474-480.
25. Momeny M., Zakidizaji M., Ghasemi R., Dehpour A.R., Rahimi-Balaei M., Abdolazimi Y., Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med. Oncol. 2010, 27:833-842.
26. Mukhina S., Mertani H.C., Guo K., Lee K.O., Gluckman P.D., Lobie P.E. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc. Natl. Acad. Sci. USA 2004, 101:15166-15171.
27. Palmero I., Pantoja C., Serrano M. P19ARF links the tumor suppressor p53 to Ras. Nature 1998, 395:125-126.
28. Perry J.K., Mohankumar K.M., Emerald B.S., Mertani H.C., Lobie P.E. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland Biol. Neoplasia 2008, 13:131-145.
29. Pettersson H.M., Karlsson J., Pietras A., Ora I., Pahlman S. Arsenic trioxide and neuroblastoma cytotoxicity. J. Bioenerg. Biomembr. 2007, 39:35-41.
30. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
31. Stevens J.J., Graham B., Walker A.M., Tchounwou P.B., Rogers C. The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells. Int J Environ Res Public Health 2010, 7:2018-2032.
32. Sun R.C., Board P.G., Blackburn A.C. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol. Cancer 2011, 10:142.
33. Supino R., Perego P., Gatti L., Caserini C., Leonetti C., Colantuono M., Zuco V., Carenini N., Zupi G., Zunino F. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Eur. J. Cancer 2001, 37:2247-2256.
34. Thiery J.P. Epithelial-mesenchymal transitions in tumor progression. Nat. Rev. Cancer 2002, 2:442-454.
35. Thijssen J.H. On the possible role of mammary-derived growth hormone in human breast cancer. Maturitas 2009, 65(Suppl 1):S13-S16.
36. Waters M.J., Conway-Campbell B.L. The oncogenic potential of autocrine human growth hormone in breast cancer. Proc. Natl. Acad. Sci. USA 2004, 101:14992-14993.
37. Wu Z.S., Yang K., Wan Y., Qian P.X., Perry J.K., Chiesa J., Mertani H.C., Zhu T., Lobie P.E. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J. Clin. Endocrinol. Metab. 2011, 96:E1619-E1629.
38. Xu S.N., Chen J.P., Liu J.P., Xia Y. Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis. Zhong Xi Yi Jie He Xue Bao 2009, 7:801-808.
39. Yoo D.R., Chong S.A., Nam M.J. Proteome profiling of arsenic trioxide-treated human hepatic cancer cells. Cancer Genomics Proteomics 2009, 6:269-274.
40. Yousefi M., Ghaffari S.H., Soltani B.M., Nafissi S., Momeny M., Zekri A., Behmanesh M., Alimoghaddam K., Ghavamzadeh A. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-kappaB expressions may play an important role in silibinin-induced response. Neurochem. Res. 2012, 37:2053-2063.
41. Zatelli M.C., Minoia M., Mole D., Cason V., Tagliati F., Margutti A., Bondanelli M., Ambrosio M.R., degli Uberti E. Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab. 2009, 94:3931-3938.
42. Zhang X., Multani A.S., Zhou J.H., Shay J.W., McConkey D., Dong L., Kim C.S., Rosser C.J., Pathak S., Benedict W.F. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res. 2003, 63:760-765.
43. 3) in endometrial carcinoma cells. Gynecol. Oncol. 2007, 105:218-222.
44. Zhu T., Starling-Emerald B., Zhang X., Lee K.O., Gluckman P.D., Mertani H.C., Lobie P.E. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res. 2005, 65:317-324.
45. Zhu Z., Mukhina S., Zhu T., Mertani H.C., Lee K.O., Lobie P.E. P44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis. Oncogene 2005, 24:3774-3785.
46. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes. Dev. 1998, 12:2424-2433.